Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

The potential of AR-V7 as a therapeutic target.

Uo T, Plymate SR, Sprenger CC.

Expert Opin Ther Targets. 2018 Feb 15:1-16. doi: 10.1080/14728222.2018.1439016. [Epub ahead of print]

PMID:
29417861
2.

Small molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer.

McClinch K, A Avelar R, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, Zaware N, Gong Y, Brautigan DL, Plymate S, Sprenger CC, Oh WK, Levine AC, Kirschenbaum A, Sfakianos JP, Sears RC, DiFeo A, Ioannou YA, Ohlmeyer M, Narla G, Galsky MD.

Cancer Res. 2018 Jan 22. pii: canres.0123.2017. doi: 10.1158/0008-5472.CAN-17-0123. [Epub ahead of print]

PMID:
29358171
3.

Allosteric alterations in the androgen receptor and activity in prostate cancer.

Uo T, Plymate SR, Sprenger CC.

Endocr Relat Cancer. 2017 Sep;24(9):R335-R348. doi: 10.1530/ERC-17-0108. Review.

4.

Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain.

Uo T, Dvinge H, Sprenger CC, Bradley RK, Nelson PS, Plymate SR.

Oncogene. 2017 Mar;36(10):1440-1450. doi: 10.1038/onc.2016.313. Epub 2016 Oct 3.

5.

Prostate cancer xenografts engineered from 3D precision-porous poly(2-hydroxyethyl methacrylate) hydrogels as models for tumorigenesis and dormancy escape.

Long TJ, Sprenger CC, Plymate SR, Ratner BD.

Biomaterials. 2014 Sep;35(28):8164-74. doi: 10.1016/j.biomaterials.2014.04.090. Epub 2014 Jun 15.

6.

The link between androgen receptor splice variants and castration-resistant prostate cancer.

Sprenger CC, Plymate SR.

Horm Cancer. 2014 Aug;5(4):207-17. doi: 10.1007/s12672-014-0177-y. Epub 2014 May 6. Review.

7.

Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.

Dean JP, Sprenger CC, Wan J, Haugk K, Ellis WJ, Lin DW, Corman JM, Dalkin BL, Mostaghel E, Nelson PS, Cohen P, Montgomery B, Plymate SR.

J Clin Endocrinol Metab. 2013 May;98(5):E820-8. doi: 10.1210/jc.2012-3856. Epub 2013 Mar 26.

8.

Capillary force seeding of sphere-templated hydrogels for tissue-engineered prostate cancer xenografts.

Long TJ, Takeno M, Sprenger CC, Plymate SR, Ratner BD.

Tissue Eng Part C Methods. 2013 Sep;19(9):738-44. doi: 10.1089/ten.TEC.2012.0388. Epub 2013 Mar 18.

9.

Aging-related alterations in the extracellular matrix modulate the microenvironment and influence tumor progression.

Sprenger CC, Plymate SR, Reed MJ.

Int J Cancer. 2010 Dec 15;127(12):2739-48. doi: 10.1002/ijc.25615. Epub 2010 Oct 8. Review.

10.

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR.

J Clin Invest. 2010 Aug;120(8):2715-30. doi: 10.1172/JCI41824. Epub 2010 Jul 19.

11.

Transforming Growth Factor-{beta}-Stimulated Clone-22 Is an Androgen-Regulated Gene That Enhances Apoptosis in Prostate Cancer following Insulin-Like Growth Factor-I Receptor Inhibition.

Sprenger CC, Haugk K, Sun S, Coleman I, Nelson PS, Vessella RL, Ludwig DL, Wu JD, Plymate SR.

Clin Cancer Res. 2009 Dec 15;15(24):7634-7641.

12.

Senescence-induced alterations of laminin chain expression modulate tumorigenicity of prostate cancer cells.

Sprenger CC, Drivdahl RH, Woodke LB, Eyman D, Reed MJ, Carter WG, Plymate SR.

Neoplasia. 2008 Dec;10(12):1350-61.

13.

Extracellular influences on tumour angiogenesis in the aged host.

Sprenger CC, Plymate SR, Reed MJ.

Br J Cancer. 2008 Jan 29;98(2):250-5. doi: 10.1038/sj.bjc.6604144. Epub 2008 Jan 8. Review.

14.

Suppression of growth and tumorigenicity in the prostate tumor cell line M12 by overexpression of the transcription factor SOX9.

Drivdahl R, Haugk KH, Sprenger CC, Nelson PS, Tennant MK, Plymate SR.

Oncogene. 2004 Jun 3;23(26):4584-93.

PMID:
15077158
15.
16.

Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1.

Plymate SR, Haugk KH, Sprenger CC, Nelson PS, Tennant MK, Zhang Y, Oberley LW, Zhong W, Drivdahl R, Oberley TD.

Oncogene. 2003 Feb 20;22(7):1024-34.

PMID:
12592389
17.
19.
20.

Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells.

Damon SE, Plymate SR, Carroll JM, Sprenger CC, Dechsukhum C, Ware JL, Roberts CT Jr.

Endocrinology. 2001 Jan;142(1):21-7.

PMID:
11145562
21.

Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor suppressor protein for prostate cancer.

Sprenger CC, Damon SE, Hwa V, Rosenfeld RG, Plymate SR.

Cancer Res. 1999 May 15;59(10):2370-5.

Supplemental Content

Loading ...
Support Center